Debrisoquine metabolism in Chinese patients with Alzheimer’s and Parkinson’s diseases

Alván G., Bechtel P., Iselius L., and Gundert-Remy U. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.Eur. J. Clin. Pharmacol. 39, 533–537.

Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., and Hetzel M. R. (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.Nature 312, 169–170.

Barbeau A., Cloutier T., Roy M., Plasse L., Paris S., and Poirier J. (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine.Lancet ii, 1213–1216.

Benitez J., Ladero J. M., Jimenez-Jimenez F. J., Martinez C., Puerto A. M. Valdivielso M. J., Llerena A., Cobaleda J., and Muñoz J. J. (1990) Oxidative polymorphism of debrisoquine in Parkinson’s disease.J. Neurol. Neurosurg. Psychiatry 53, 289–292.

Bosron W. F. and Li T. K. (1986) Genetic polymorphism of human liver alcohol and aldehyde dehydrogenase, and their relationship to alcohol metabolism and alcoholism.Hepatology 6, 502–510.

Brosen K., Gram L. F., Haghfelt T., and Bertilsson L. (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.Phamacol. Toxicol. 60, 312–314.

Calne D. B. and Langston J. W. (1983) Aetiology of Parkinson’s disease.Lancet 2, 1457–1475.

Eichelbaum M., Mineshita S., Ohnhaus E. E., and Zekorn C. (1986) The influence of enzyme induction on polymorphic sparteine oxidation.Br. J. Clin. Pharmacol. 22, 49–53.

Evans D. A. P., Mahgoub A., Sloan T. P., Idle J. R., and Smith R. L. (1980) A family and population study of the genetic polymorphism of debrisoquine in a white British population.J. Med. Genet. 17, 102–105.

Fonne-Pfister R., Bargetzi M. J., and Meyer U. A. (1987) MPTP, the neurotoxin inducing Parkinson’s disease is a potent competitive inhibitor of human and rat cytochrome P-450 isozymes (P-450bufI, P-450db1) catalyzing debrisoquine 4-hydroxylation.Biochem. Biophys. Res. Commun. 148, 1144–1150.

Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin, H. V., Hardwick, J. P., and Meyer U. A. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.Nature 331, 442–446.

Gough A. C., Miles J. S., Spurr N. K., Moss J. E., Gaedigk A., Eichelbaum M., and Wolf C. R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus.Nature 347, 773–776.

Gudjonsson O., Sanz E., Alván G., Aquilonius S. M., and Reviriego J. (1990) Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson’s disease.Br. J. Clin. Pharmac. 30, 301–302.

Idle J. R. (1989) Poor metabolizers of debrisoquine reveal their true colours.Lancet ii, 1097.

Kaisary A., Smith P., Jaczq E., McAllister C. B., Wilkinson G. R., Ray W. A., and Branch R. A. (1987) Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors.Cancer Res. 47, 5488–5493.

Katzman R. (1986) Alzheimer’s disease.N. Eng. J. Med. 314, 964–973.

Lou Y. C., Ying L., Bertilsson L., and Sjöqvist F. (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population.Lancet ii, 852–853.

McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease.Neurology 34, 939–944.

Nakamura K. (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations.Clin. Pharmacol. Ther. 38, 402–408.

Poirier J., Roy M., Campanella G., Cloutier T., and Paris S. (1987) Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs.Lancet ii, 386.

Steiner E., Iselius L., Alván G., Lindsten J., and Sjöqvist F. (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine.Clin. Pharmacol. Ther. 38, 394–401.

Steventon G. B., Heafield M. T. E., Sturman S., Waring R. H., and Williams A. C. (1990) Zenobiotic metabolism in Alzheimer’s disease.Neurology 40, 1095–1098.

Syvälathi E. K. G., Lindberg R., Kallio J., and DeVocht M. (1986) Inhibitory effects of neuropleptics on debrisoquine oxidation in man.Br. J. Clin. Pharmacol. 22, 89–92.

Westwood B. E., Harman P. J., and Mashford M. L. (1986) Liquid chromatographic assay for debrisoquine and 4-hydroxydebrisoquine in urine.J. Chromatogr. 374, 200–203.

Yue Q. Y., Bertilsson L., Dahl-Puustinen M. L., Säwe J., Sjöqvist F., Johansson I., and Ingelman-Sundberg M. (1990) Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.Lancet ii, 870.